Eliot X. Murphy
Biography
Overview
Eliot Murphy is an associate in White & Case's Global Mergers & Acquisitions Practice Group and a member of the firm's Global Private Equity Industry Group. Eliot represents corporate clients and private equity funds in domestic and cross-border mergers, acquisitions, divestitures, equity investments and joint ventures in a broad range of industries. He also advises complex international organizations in corporate governance matters.
Eliot earned his Juris Doctor degree, Business Law Certificate and Media & Entertainment Law Certificate from the University of Southern California Gould School of Law. At USC, he was a member of the Hale Moot Court Honors Program, Mediation Clinic and Student Bar Association Executive Board and served as the Vice President of the Business Law Society and Entertainment Law Society. During law school, Eliot won UCLA's Lowell Milken Institute for Business Law and Policy's national Transactional Law Competition, receiving awards for Best Draft Agreement and Best Overall.
Eliot is a member of the USC Alumni Association’s New York Regional Committee for the Gould School of Law.
Experience
Representation of EnCap Investments, L.P., a leading provider of growth capital to the independent sector of the US energy industry, in the sale of Broad Reach Power's battery storage business to French multinational utility company, ENGIE, for a total equity value in excess of US$1 billion.
Representation of Brookfield Renewable, a leading global operator and developer of renewable power and transition assets, in the sale of three operational, nonconventional renewable energy projects in Uruguay to Cubico Sustainable Investments, one of the world's largest privately owned renewable energy companies.
Representation of Harvest Partners, LP in the sale of Concentric, LLC, a top provider of industrial power solutions in North America, to Mitsubishi Heavy Industries, Ltd., one of the world's leading industrial groups.
Representation of Azurity Pharmaceuticals, Inc. on its acquisition of Slayback Pharma, LLC from existing investors including KKR, a leading global investment firm, and Everstone Capital.
